載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$140.58
+US$7.97 · +6.01%
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
前收盤價
US$140.58
+US$7.97 · +6.01%
盤中時間採用ET。市場資料可能有所延遲。
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
日內區間
目前US$140.58
52週區間
目前US$140.58
盤中時間採用ET。市場資料可能有所延遲。
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
日內區間
目前US$140.58
52週區間
目前US$140.58
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$106.14
下跌空間 24.50%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM1.44億0.18%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.32億1.33%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI9777.5萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Biotechnology ETFIBB4332.4萬0.41%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS3710.41萬0.11%338.69億 USD0.31%US$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA3144.58萬0.14%218.24億 USD0.03%US$32.79+0.40%
Vanguard Extended Market ETFVXF3001.84萬0.03%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO1884.7萬0.10%180億 USD0.06%US$112.66+0.50%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
